Raizer, J J <br/><br/>
A phase II study of bevacizumab and erlotinib after radiation  and temozolomide in MGMT unmethylated GBM patients.  [electronic resource] 

 -  Journal of neuro-oncology  Jan 2016 
 - 185-192 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7373 
<br/><br/><label>Standard No.: </label>10.1007/s11060-015-1958-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Brain Neoplasms--drug therapy<br/>DNA Methylation<br/>DNA Modification Methylases--genetics<br/>Dacarbazine--adverse effects<br/>Disease-Free Survival<br/>Erlotinib Hydrochloride--therapeutic use<br/>Female<br/>Glioblastoma--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Radiotherapy--adverse effects<br/>Temozolomide<br/>Treatment Outcome<br/>Young Adult